Wqqq_老虎社区_美港股上老虎

rachellll
2022-01-13

Wqqq

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal

Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradat

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":694421209,"tweetId":"694421209","gmtCreate":1642084162295,"gmtModify":1642084163402,"author":{"id":3586435391928672,"idStr":"3586435391928672","authorId":3586435391928672,"authorIdStr":"3586435391928672","name":"rachellll","avatar":"https://static.tigerbbs.com/7855a29f75174783f11b5102e8a7c8ba","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":29,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wqqq</p></body></html>","htmlText":"<html><head></head><body><p>Wqqq</p></body></html>","text":"Wqqq","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/694421209","repostId":1128321741,"repostType":4,"repost":{"id":"1128321741","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642082676,"share":"https://www.laohu8.com/m/news/1128321741?lang=&edition=full","pubTime":"2022-01-13 22:04","market":"us","language":"en","title":"Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1128321741","media":"Benzinga","summary":"Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradat","content":"<html><head></head><body><p><b>Salarius Pharmaceuticals Inc</b> has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from <b>DeuteRx LLC</b>.</p><ul><li>The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).</li><li>&#34;This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,&#34; stated David Arthur, CEO of Salarius.</li><li>SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body&#39;s normal protein-degradation processes and induce selective elimination of cancer-causing proteins.</li><li>Salarius plans to begin the first clinical trial in 2023.</li><li>As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&amp;D of future products.</li><li>Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.</li><li>SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.</li><li>Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.</li><li><b>Price Action:</b> SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-13 22:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>Salarius Pharmaceuticals Inc</b> has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from <b>DeuteRx LLC</b>.</p><ul><li>The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).</li><li>&#34;This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,&#34; stated David Arthur, CEO of Salarius.</li><li>SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body&#39;s normal protein-degradation processes and induce selective elimination of cancer-causing proteins.</li><li>Salarius plans to begin the first clinical trial in 2023.</li><li>As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&amp;D of future products.</li><li>Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.</li><li>SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.</li><li>Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.</li><li><b>Price Action:</b> SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128321741","content_text":"Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from DeuteRx LLC.The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).\"This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,\" stated David Arthur, CEO of Salarius.SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body's normal protein-degradation processes and induce selective elimination of cancer-causing proteins.Salarius plans to begin the first clinical trial in 2023.As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&D of future products.Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.Price Action: SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":919,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal

评论（1）

热议股票